Abstract
It is well established that liquid biopsies (LB) are non-inferior to tissue biopsies (TB) to identify actionable genetic alterations (AGA) in patients with metastatic non-small cell lung cancer (mNSCLC). Importantly, LB are able to report next generation sequencing (NGS) results significantly faster than TB NGS and overcome the logistical barriers of finding and shipping tissue samples for sequencing. This study aimed to illustrate that LB can be used first in treatment decision making for mNSCLC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
